The biopharmaceutical firm reported a $0.17 miss on non-GAAP EPS and a $7.14M revenue shortfall for the quarter.
Ligand Pharmaceuticals posted a non-GAAP EPS of $1.63, missing estimates by $0.17, as revenue reached $51.72M, $7.14M below expectations. The results reflect weaker-than-anticipated performance in its core business segments.
Analysts had projected stronger earnings and revenue growth, following prior quarter trends. The company’s revenue of $51.72M compares to higher consensus estimates, signaling potential challenges in demand or execution.
Shares may face pressure as investors reassess growth prospects amid the earnings miss.